Bend, Oregon – May 5, 2011 – Clear Catheter Systems, Inc., today announced that the PleuraFlow® Active Tube Clearance® System will be featured in the “ICU of the Future” exhibit at the annual American Association of Thoracic Surgery Meeting in Philadelphia. New for 2011, the ICU of the Future allows AATS surgeon members to view first hand what the future holds for cardiothoracic critical care. The PleuraFlow® Active…
Read more
Bend, OR—April 6, 2011—Clear Catheter Systems, Inc., today announced that the PleuraFlow® Active Tube Clearance® System has been awarded a 2011 Medical Design Excellence Award. The Medical Design Excellence Awards (MDEA) competition is the premier awards program for the medical technology community. Entries are evaluated on the basis of design and engineering features that improve healthcare delivery, change traditional medical attitudes or practices, and provide enhanced benefits to…
Read more
Bend, OR—December 13, 2010—Clear Catheter Systems, Inc, a Bend, Oregon-based medical device company, announced today that it has received US Food and Drug Administration clearance for its innovative PleuraFlow® Active Tube Clearance® System. This is a device that can be widely deployed in the post operative management of patients requiring heart and lung surgery. The company has approval to market the device in Europe and Canada, and this…
Read more
There was an interesting article on bleeding after heart surgery in the American Heart Journal this month. The Title is “Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting.” The Citation is: Am Heart J 2011 Feb;161(2):404-10. The focus of the study is the impact of Plavix (Clopidogrel) on bleeding after heart surgery. The investigators found that major bleeding happened in 73% of patients loaded…
Read more
Clear Catheter Systems recently attended the German Society of Thoracic and Cardiovascular Surgery in Stuttgart, Germany. Perhaps it was fitting that the motto of the program was “Panta Rhei”, which means “everything flows.” We had some great meetings discussing the importance of adequate chest tube flow with surgeons from all over the region, including surgeons from Germany, Austria and Switzerland. Multiple discussions were held about chest tube clogging…
Read more
The company continues to develop and protect its intellectual property. In 2010, the company filed additional patents and was granted patent approvals, including a US patent that was issued with claims adding protection for the active tube clearance platform.
Read more
Jim Fee joined our board as a representative of the Oregon Angel Fund. Mr. Fee has spent 40 years in the medical device industry having most recently served as Vice-President and General Manager Welch Allyn Defibrillation and, President of Medical Research Laboratories, a Welch Allyn Company. Mr. Fee spent 12 years at Protocol Systems as VP Global Sales and Marketing from start-up through public offering and acquisition by…
Read more
The company held its annual Scientific Advisory Board Meeting at the STS in San Diego in late January. The event included leading surgeons from Cleveland, LA, Minneapolis, Houston and Milwaukee representing some of the top heart surgery programs in the world. Also attending were current and prospective distribution partners as well as two board members (George Trutza and Jim Fee). This was an important opportunity to obtain clinical…
Read more